NKCx Histopathological outcome* within 12 months after cervix cytology in 2018 |
611 Gävle |
Benign | CIN1 | CIN2 | CIN3 | AIS | Cancer | Other | PAD missing | Total | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytology | Count | Pct | Count | Pct | Count | Pct | Count | Pct | Antal | Andel | Count | Pct | Count | Pct | Count | Pct | Count | Pct |
Benign sample | 69 | 0.4% | 2 | 0.0% | . | . | 1 | 0.0% | . | . | 1 | 0.0% | 3 | 0.0% | 16132 | 99.5% | 16208 | 100.0% |
ASCUS | 31 | 6.4% | 44 | 9.1% | . | . | 43 | 8.9% | 3 | 0.6% | 2 | 0.4% | 5 | 1.0% | 353 | 73.4% | 481 | 100.0% |
CIN1 | 31 | 17.8% | 37 | 21.3% | . | . | 45 | 25.9% | . | . | 1 | 0.6% | 1 | 0.6% | 59 | 33.9% | 174 | 100.0% |
Unclear atypia | 1 | 12.5% | 1 | 12.5% | . | . | 4 | 50.0% | . | . | 2 | 25.0% | . | . | . | . | 8 | 100.0% |
ASC-H | . | . | . | . | . | . | 1 | 50.0% | . | . | 1 | 50.0% | . | . | . | . | 2 | 100.0% |
CIN3 | 2 | 4.4% | 7 | 15.6% | . | . | 34 | 75.6% | 1 | 2.2% | 1 | 2.2% | . | . | . | . | 45 | 100.0% |
Total | 134 | 0.8% | 91 | 0.5% | . | . | 128 | 0.8% | 4 | 0.0% | 8 | 0.0% | 9 | 0.1% | 16544 | 97.8% | 16918 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (CIN1) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81401, M81403 |